Twist Bioscience Co. (NASDAQ:TWST) Receives $51.22 Average Target Price from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $51.78.

Several research analysts have recently issued reports on the company. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th.

Insider Transactions at Twist Bioscience

In related news, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the sale, the senior vice president now owns 121,013 shares in the company, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 98,118 shares of company stock valued at $4,391,151. Corporate insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the second quarter worth $43,000. Blue Trust Inc. boosted its holdings in shares of Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the second quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Twist Bioscience Trading Up 1.9 %

TWST stock opened at $41.89 on Tuesday. Twist Bioscience has a 12-month low of $23.07 and a 12-month high of $60.90. The company has a market capitalization of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78. The business’s fifty day moving average price is $43.93 and its 200 day moving average price is $46.15.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.